Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Regeneron Pharmaceuticals Inc. Stock

Price
Target price
€480.10

€480.10

0.040%
0.2
0.040%
€964.27
 
09:50 / Tradegate WKN: 881535 / Symbol: REGN / Name: Regeneron / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Wizard

Regeneron Pharmaceuticals Inc. Stock

There is nearly no change for the Regeneron Pharmaceuticals Inc. stock today. Compared to yesterday it only changed by €0.20.
With 48 Buy predictions and 2 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
Based on the current price of 480.1 € the target price of 964 € shows a potential of 100.79% for Regeneron Pharmaceuticals Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Regeneron Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Regeneron Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Regeneron Pharmaceuticals Inc. 0.040% 0.777% -1.214% -54.469% -29.051% -21.675% -7.176%
Incyte Corp. 3.690% 10.147% 25.179% 31.223% 11.656% 1.987% -9.307%
Exact Sciences -1.030% -4.691% -13.514% -28.224% -29.386% -7.737% -47.939%
Amgen Inc. -0.300% 1.228% -2.157% -15.930% -1.317% 2.169% 21.439%

Comments

Prediction Buy
Perf. (%) 0.82%
Target price 696.128
Change
Ends at 11.08.26

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Truist Financial Corporation from $940.00 to $812.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Truist Financial Co. 
0
Report Share
11.08.25
Prediction Buy
Perf. (%) -2.87%
Target price 552.896
Change
Ends at 04.08.26

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at BMO Capital Markets from $600.00 to $640.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

BMO Capital Markets 
0
Report Share
04.08.25
Prediction Buy
Perf. (%) 0.00%
Target price 642.106
Change
Ends at 10.07.26

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $755.00 to $754.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Morgan Stanley 
0
Report Share
10.07.25
Show more
Not a member yet? Sign up for free!

News

Regeneron (REGN) Q2 EPS Jumps 53%
Regeneron (REGN) Q2 EPS Jumps 53%

Regeneron (NASDAQ:REGN), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025. The headline news: the company posted Non-GAAP

TheMotleyFool 
0 02.08.25
2 Healthcare Stocks That Are Losing to the S&P 500 This Year: https://g.foolcdn.com/editorial/images/825381/doctor-and-patient-talking.jpg
2 Healthcare Stocks That Are Losing to the S&P 500 This Year

Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky

TheMotleyFool 
0 27.07.25
2 Beaten-Down Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/823408/person-getting-vaccinated.jpg
2 Beaten-Down Stocks to Buy and Hold

Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy. Regardless of what

TheMotleyFool 
0 05.07.25